Literature DB >> 17020684

[Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations].

Nuria Fernández-Mosteirín1, Carlos Salvador-Osuna, José Antonio García-Erce, Elisa Orna, Gonzalo Pérez-Lungmus, Manuel Giralt.   

Abstract

BACKGROUND AND
OBJECTIVE: Large-volume erythrocytapheresis (EA) is an useful and speedy method to treat iron overload (IO). We assesed the efficacy of EA in patients with HFE gene mutations and IO compared to the classical phlebotomies. PATIENTS AND
METHOD: Data from 9 patients with IO treated with EA, using a discontinuous flow cell separator as a single needle procedure, for a period of 2 years, were compared to 9 matched patients who underwent conventional phlebotomies.
RESULTS: The mean volume of red blood cells removed in each EA was 275 ml, with a median reduction of 23 g/l for haemoglobin and 55 microg/l for serum ferritin levels (vs. 17 microg/l between phlebotomies). The liver function test returned to normal values in 4 out of 5 patients undergoing EA, but none of the phlebotomies. The time required to achieve iron depletion was 3 times shorter in EA group.
CONCLUSIONS: EA is an effective and safe procedure that achieves iron depletion more quickly than manual phlebotomies. Nevertheless, to determine its cost-effectiveness, economical, prospective, randomized studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020684     DOI: 10.1157/13092766

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  2 in total

1.  Iron chelators reverse organ damage in type 4B hereditary hemochromatosis: Case reports.

Authors:  Ling-Yan Wu; Zhen-Ya Song; Qing-Hai Li; Li-Jun Mou; Ying-Ying Yu; Si-Si Shen; Xiao-Xiao Song
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

2.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.